Anistreplase

Trade Names:Eminase- Powder for injection, lyophilized 30 units (potency is expressed in units of anistreplase by using a reference standard that is specific for anistreplase and is not comparable with units used for other fribrinolytics)

Pharmacology

Aids in dissolution of blood clots.

Pharmacokinetics

Metabolism

Deacylation of anistreplase forms lys-plasminogen-streptokinase activator complex (active).

Elimination

T _½ of fibrolytic activity is approximately 94 min.

Indications and Usage

Lysis of obstructing coronary thrombi for management of acute MI.

Contraindications

Hypersensitivity to streptokinase; active internal bleeding; history of cerebrovascular accident; recent (within 2 mo) intracranial or intraspinal surgery or trauma; intracranial neoplasm; arteriovenous malformation or aneurysm; known bleeding diathesis; uncontrolled hypertension.

Dosage and Administration

IV 30 units over 2 to 5 min into IV line or vein. Reconstitute powder with 5 mL of sterile water for injection. Do not shake vial during reconstitution; try to minimize foaming. Do not further dilute reconstituted anistreplase.

Storage/Stability

Store lyophilized anistreplase under refrigeration. Discard any reconstituted anistreplase not administered within 30 min of reconstitution.

Drug Interactions

May increase risk of bleeding.

Incompatibility

Do not add to any infusion fluids. Do not add other medications to vial or syringe containing anistreplase.

Laboratory Test Interactions

Can cause decreases in plasminogen and fibrinogen levels and increases in thrombin time, activated PTT and PT, making results of coagulation tests unreliable.

Adverse Reactions

Cardiovascular

Arrhythmia and conduction disorders; hypotension.

Hematologic

Bleeding at puncture site, nonpuncture-site hematoma; hematuria; hemoptysis; GI hemorrhage; intracranial bleeding; mouth and gum hemorrhage; epistaxis; ocular hemorrhage; nonspecific hemorrhage.

Precautions

Pregnancy

Category C .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Hypersensitivity

Rarely, anaphylactic and anaphylactoid reactions (with bronchospasm or angioedema) may occur.

Arterial puncture

If arterial puncture is necessary after administration of anistreplase, it is preferable to use upper extremity vessel that is accessible to manual compression. Apply pressure dressing; check puncture site frequently for evidence of bleeding. Control minor bleeding with manual pressure.

Epinephrine

Have epinephrine and emergency treatment provisions available during administration of anistreplase.

Readministration

Because of formation of antistreptokinase antibody, anistreplase may not be effective if administered more than 5 day to 6 mo after prior anistreplase or streptokinase therapy or after streptococcal infection.

Patient Information

• Explain to patient the need for bedrest and minimal handling of patient.
• Instruct patient to report the following symptoms to health care provider: bruising, bleeding, hypersensitivity reactions (eg, urticaria, flushing, itching, rashes).
• Caution patient to avoid sudden position changes to prevent orthostatic hypotension.